At 12.2% CAGR, North America Botulinum Toxin Market is Projected to be Worth US$ 12,072.60 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the North America botulinum toxin market was valued at US$ 4,801.29 million in 2023 and is expected to reach US$ 12,072.60 million by 2031, registering a CAGR of 12.2% from 2023 to 2031. Rising popularity of noninvasive aesthetics procedures and increasing use of botulinum toxin for enhancing facial aesthetics are among the critical factors attributed to drive the North America botulinum toxin market growth.

Noninvasive procedures include facial rejuvenation, injections which includes botulinum toxin, calcium hydroxyapatite, and hyaluronic acid, and others. These procedures help reduce cellulite, wrinkles, facial lines, and unwanted fat with minimal side effects. The concept of natural rejuvenation is based on a comprehensive, multilayered, three-dimensional approach that combines multiple techniques and active ingredients in procedures such as volume enlargement, skin relaxation, reshaping, volume repositioning, skin tightening, and surface renewal, depending on specific needs of patients. The most often used non-surgical face procedures are chemical peels, laser skin resurfacing, soft tissue fillers, and Botox. Unlike surgical procedures that are associated with greater risks, minimally invasive procedures benefit patients through faster recovery, lesser scarring, limited stress, and better patient satisfaction. Moreover, changing consumer views about wellness, beauty, and good aging results in a better understanding and acceptance of aesthetics worldwide. According to the International Society of Aesthetic Plastic Surgery (ISAPS), the number of nonsurgical procedures increased by 19.9% in 2021 compared to 2020. The total number of nonsurgical procedures was 17.5 million in 2021. Thus, an upsurge in the adoption of noninvasive aesthetic procedures is driving the growth of the botulinum toxin market.

On the contrary, side effects of botulinum toxin hamper the growth of North America botulinum toxin market.

Based on product, the North America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held 98.3% share of North America botulinum toxin market share in 2023, amassing US$ 4,721.11 million. It is projected to garner US$ 11,934.23 million by 2031 to register 12.3% CAGR during 2023–2031.

In terms of application, the North America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held 56.6% share of North America botulinum toxin market in 2023, amassing US$ 2,716.77 million. It is anticipated to garner US$ 7,198.56 million by 2031 to expand at 13.0% CAGR during 2023–2031. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.

By end user, the North America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held 49.7% share of North America botulinum toxin market in 2023, amassing US$ 2,388.11 million. It is projected to garner US$ 6,368.10 million by 2031 to expand at 13.0% CAGR from 2023 to 2031.

Based on country, the North America botulinum toxin market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 95.3% share of North America botulinum toxin market in 2023. It was assessed at US$ 4,574.57 million in 2023 and is likely to hit US$ 11,366.36 million by 2031, registering a CAGR of 12.0% during 2023–2031.

Key players operating in the North America botulinum toxin market are Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Aquavit, Revance Therapeutics Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd, among others.

• In February-2022, Merz Therapeutics is expanding its strategic partnership with Vensica Therapeutics as the Merz Group invests up to US$3 million in the Israeli start-up. This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN) for the innovative ultrasound-assisted delivery catheter of Vensica. Merz is thus executing its contractually agreed option to participate in Vensica’s Series C financing round and invest further in the start-up.
• In August-2021, Merz Therapeutics and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced that they have entered into a strategic license and collaboration agreement to deliver botulinum neurotoxin A (XEOMIN)to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder, interstitial cystitis, and other urology indications.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com